71
71
50
50
68
68
54
54
42
42
52
52
70
70
95
95
130
130
39
39
2020
2011
Company (1K)University (8)Investor (4)Research Institution (3)Hospital (2)
1 - 10 of 1,013
Sort by
Patent
Publication NumberUS 20200157641Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-11-14Publication Date2020-05-21
Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene. The average expression of the 5′ portion of the target gene is compared with …
SEC Filing
Accession Number0001022079-20-000120Form Type8-KAcceptance Date2020-05-21
0001022079 2020-05-19 2020-05-19 false 0001022079 8-K 2020-05-19 Quest Diagnostics Inc DE 001-12215 16-1387862 500 Plaza Drive Secaucus, NJ 07094 (973) 520-2700 false false false false Common Stock, $0.01 Par Value DGX NYSE false
Patent
Publication NumberUS 20200158741Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2020-01-13Publication Date2020-05-21
The invention relates to the detection of DHA and EPA. In a particular aspect, the invention relates to methods for detecting DHA and EPA by mass spectrometry and kits for carrying out such methods.
Patent
Publication NumberUS 20200158688Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2020-01-21Publication Date2020-05-21
Provided are methods of detecting the presence or amount of a dihydroxyvitamin D metabolite in a sample using mass spectrometry. The methods generally comprise ionizing a dihydorxyvitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. In certain preferred embodiments the methods include immunopurifying the dihydroxyvitamin D metabolites prior to mass spectrometry. Also provided are methods to detect t…
Patent
Publication NumberUS 20200162634Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2020-01-27Publication Date2020-05-21
Systems and methods are provided though which a transaction, e.g., in a multi-tier, distributed application may be initiated from a portable or hand-held device, such as a smartphone. A computer system or systems, possibly remote from the device, may approve the transaction, complete it, or both, and the remote computer system or systems may cause a document to be printed, e.g., by a printer physically proximate to the device. Aspects of the invention are illustrated by embodiments in which a…
Patent
Publication NumberUS 20200157527Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-11-22Publication Date2020-05-21
The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with …
Patent
Publication NumberUS 10655161Filing StatusIssued PatentAvailabilityUnknownFiling Date2014-12-03Publication Date2020-05-19
Provided herein are methods for the diagnosis, prognosis, or management of diseases, such as cancer, by measuring the tyrosine kinase activity in acellular body fluids. Further provided are methods of predicting response to therapy in certain populations of cancer patients by contacting an acellular body fluid sample from a patient with a test agent, such as a tyrosine kinase inhibitor, and then measuring the effect of the test agent on tyrosine kinase activity in the sample.
Patent
Publication NumberUS 10655179Filing StatusIssued PatentAvailabilityUnknownFiling Date2018-01-08Publication Date2020-05-19
The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided.
SEC Filing
Accession Number0000947871-20-000458Form Type8-KAcceptance Date2020-05-13
0001022079 2020-05-11 2020-05-11 iso4217:USD shares iso4217:USD shares 0001022079 false 8-K 2020-05-11 Quest Diagnostics Incorporated DE 001-12215 16-1387862 500 Plaza Drive Secaucus NJ 07094 (973) 520-2700 false false false false Common Stock, $0.01 Par Value DGX NYSE false
Patent
Publication NumberUS 10648989Filing StatusIssued PatentAvailabilityUnknownFiling Date2017-05-23Publication Date2020-05-12
Methods are provided for determining the amount of an IGF-I and/or IGF-II protein in a sample using high resolution/high accuracy mass spectrometry. The methods generally comprise enriching an IGF-I and/or IGF-II protein in a sample, ionizing an IGF-I and/or IGF-II protein from the sample to generate IGF-I and/or IGF-II protein ions, and determining the amount of IGF-I and/or IGF-II protein ions with high resolution/high accuracy mass spectrometry.
We found 1,013 documents that match your Search
Research Grants: 2
Patents: 706
Clinical Trials: 2
SEC Filings: 303

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in